Spinifex

Spinifex

Portfolio   Contact:   Peter Devine Professor Maree Smith Spinifex is a start-up company from the University of Queensland that is developing a potential first-in-class oral treatment for neuropathic pain and related symptoms without central nervous system side...
Fibrotech

Fibrotech

Portfolio   Contact:   Peter Devine Professor Darren Kelly Fibrotech is a spin-out of the University of Melbourne, developing drugs to treat fibrosis based on the work of Professor Darren Kelly. In April 2014, Fibrotech reached an agreement with Shire...
Hatchtech

Hatchtech

Portfolio   Contact:   Peter DevineWebsite:  www.hatchtech.com.au This investment won the Australian Venture Capital Association ‘Best Early Stage Venture Deal of 2016’ and Hatchtech’s human head lice treatment received FDA approval in July...
Fultec

Fultec

Portfolio   Contact:   Peter Devine The Fultec device is a protection switch that virtually instantaneously disconnects vulnerable equipment from the disturbed input power terminal and then reconnects the system after the surge has passed. The device offers...
QRxPharma

QRxPharma

Portfolio   Contact:   Peter Devine In May 2007, QRx-Pharma merged with a US based biotechnology company (CNSCo Inc) and raised $50 million via an ASX listing at a pre-investment valuation of $100 million (ASX: QRX). At that time, Uniseed got back more than the...